GSK and Amgen Add Medicines to TrumpRx — 54 Drugs Now Listed, Discounts Up to 80%

The Trump administration's flagship prescription drug affordability programme has taken another significant step forward. Fox Business has exclusively reported that GlaxoSmithKline (GSK) and Amgen are being added to TrumpRx.gov — bringing the total number of prescription medications listed on the platform to 54 drugs from six pharmaceutical companies, all offered under Most-Favoured-Nation (MFN) pricing agreements negotiated under pressure from President Trump and the threat of pharmaceutical tariffs. "GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favoured-nations pricing marks another milestone for President Trump's affordability push," White House spokesman Kush Desai told FOX Business. Here are all the key facts.

What Is TrumpRx? The Platform Explained

TrumpRx launched with the tagline "Delivering the lowest prescription prices in the world for Americans." The platform functions as a direct-to-consumer pricing portal — it does not sell medications directly. Instead, patients use TrumpRx as a portal to access manufacturers' websites and purchase the medications directly from them. TrumpRx provides users with coupons that can be redeemed at pharmacies and/or manufacturer DTC sites. TrumpRx is available to American citizens. However, specific medications have unique qualifications that users must meet to obtain a coupon. Many medications on the site are not providing coupons to anyone enrolled in government, state, or federally funded medical or prescription insurance coverage.

The platform was first announced in September 2025, officially launched on February 5, 2026, and is expanding rapidly as more pharma companies sign MFN agreements. For authoritative and up-to-date information on every drug listed, eligibility criteria, and participating companies, Pharmacy Times' comprehensive MFN Agreement Roundup — which covers all 16 agreements struck so far — is the most complete institutional reference available for healthcare providers and patients.

Amgen's TrumpRx Additions: Up to 80% Off Across 3 Drugs

Amgen is adding three key medications to TrumpRx — and the discounts are substantial:

  • Amjevita (adalimumab-atto — Humira biosimilar): Original price of $1,484, now available on TrumpRx.gov for $299 — an 80% discount. The medication treats rheumatoid arthritis, psoriasis, and ulcerative colitis.
  • Aimovig (erenumab-aooe): Amgen plans to list Aimovig for a discount of 62%. Aimovig is a self-administered injectable monoclonal antibody designed for migraine prevention.
  • Repatha (evolocumab): Repatha is also listed for a 62% discount. Repatha is Amgen's cholesterol-lowering injection (evolocumab) used to reduce cardiovascular risk in patients with high LDL cholesterol. It will be available through TrumpRx at $239 according to White House fact sheets.

Amgen announced the expansion of its AmgenNow direct-to-consumer programme to include these medications as self-administered injectable monoclonal antibody therapies — making them available at a discounted monthly price through the TrumpRx portal.

GSK's TrumpRx Additions: Respiratory Portfolio at 10–55% Discounts

GSK is listing four respiratory medications — consistent with its broader commitment to lower the cost of its inhaled respiratory portfolio for American patients:

  • Incruse (umeclidinium — COPD treatment): GSK will discount Incruse at 55% of the retail price. The drug treats COPD and will be listed at $159.
  • Arnuity (fluticasone furoate — asthma): GSK plans to list Arnuity at discounts ranging from 10% to 51%.
  • Relenza (zanamivir — influenza treatment): Listed at discounts in the 10–51% range.
  • Anoro (umeclidinium/vilanterol — COPD maintenance): Listed at discounts in the 10–51% range.

GSK entered into an agreement with the US administration on December 19, 2025, to lower the cost of prescription medicines for American patients. The agreement covers both GSK and ViiV Healthcare and, assuming expected implementation, excludes both companies from Section 232 tariffs for three years. Along with launching new products at MFN pricing, GSK also intends to make most of its inhaled respiratory portfolio available to patients on a DTC platform that will offer savings of up to 66%. GSK will also help bolster the US supply chain by donating a reserve of albuterol to the country's Strategic Active Pharmaceutical Ingredients Reserve.

The Full TrumpRx Pharmaceutical Roster: All 6 Companies

With the addition of GSK and Amgen, TrumpRx now features a total of 54 prescription medications from six pharmaceutical companies that have signed on to most-favoured-nation pricing under pressure from President Donald Trump and the threat of tariffs. The six participating companies as of this announcement are: Pfizer, Eli Lilly, Novo Nordisk (founding participants) and now Amgen, GSK — with a sixth company in the lineup. The wider TrumpRx ecosystem extends significantly further: companies including Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AstraZeneca, Pfizer, Eli Lilly, and Novo Nordisk have all made deals with the Trump administration to be included on TrumpRx.

The MFN Policy: How Tariff Pressure Made This Happen

Trump sent letters to the leaders of 17 large pharma companies back in July 2025, demanding that they match US prices of their new drugs with the lowest prices offered in other developed nations — the concept of most-favoured-nation pricing. The latest batch of accords follows similar MFN deals struck by Pfizer, AstraZeneca, Merck KGaA's EMD Serono, Eli Lilly and Novo Nordisk in recent months. Many of these companies faced steep Section 232 tariffs by the Trump administration, which granted them "grace periods" after they agreed to MFN deals. The three-year tariff exemption offered to compliant pharma companies is the central incentive mechanism — making TrumpRx participation financially rational even for companies that would prefer to maintain higher US list prices.

Under the Biden administration, Bureau of Labor Statistics data shows prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased just 0.2% from January 2025 through the latest data from February 2026. The White House uses this comparison as the primary measure of the programme's success.

Key Facts at a Glance

  • Platform: TrumpRx.gov
  • Launch Date: February 5, 2026
  • Total Medicines (Post-GSK/Amgen Addition): 54 prescription medications
  • Participating Companies (TrumpRx-listed): 6 (including Pfizer, Eli Lilly, Novo Nordisk, Amgen, GSK)
  • Total MFN Agreement Companies (Broader): 14+ including Boehringer, BMS, Gilead, Merck, Novartis, Sanofi, AZ
  • Amgen — Amjevita Price on TrumpRx: $299 (vs $1,484 list — 80% discount)
  • Amgen — Aimovig Discount: 62%
  • Amgen — Repatha Price on TrumpRx: $239 (62% discount)
  • GSK — Incruse Price on TrumpRx: $159 (55% discount)
  • GSK — Arnuity, Relenza, Anoro: 10%–51% discounts
  • GSK DTC Portfolio Savings (Max): Up to 66%
  • GSK Tariff Relief: Section 232 tariff exemption for 3 years (effective Dec 19, 2025)
  • Platform Type: Coupon aggregator / DTC pricing portal (does NOT sell directly)
  • Insurance Eligibility: Most coupons NOT available to government-sponsored insurance enrollees
  • Prescription Drug Price Change (Trump admin, Jan 2025–Feb 2026): +0.2%
  • Prescription Drug Price Change (Biden admin, Jan 2021–Jan 2025): +10.4%
  • Cost Plus Drugs (Mark Cuban): API integration with TrumpRx for real-time pricing
  • White House Spokesman: Kush Desai
  • Fox Business Report Status: Exclusive / Confirmed by White House

Conclusion

The addition of GSK and Amgen to TrumpRx.gov — taking the platform to 54 listed medicines from 6 companies — is a meaningful expansion of what is becoming the most ambitious US prescription drug affordability initiative in a generation. For American patients with rheumatoid arthritis, psoriasis, migraines, high cholesterol, COPD, and asthma who pay out-of-pocket, the discounts are genuinely transformative: 80% off Amjevita, 62% off Aimovig and Repatha, and 55% off Incruse represent real dollar savings that materially change treatment access and adherence economics.

The wider policy picture is equally significant. With 14+ pharma companies now holding MFN agreements, Section 232 tariff exemptions as the compliance incentive, and a White House pointing to a +0.2% drug price change versus the Biden era's +10.4%, the Trump administration has created a durable structural shift in how pharmaceutical pricing negotiations in the US will operate going forward — regardless of which party next occupies the White House. For patients, the next step is straightforward: visit TrumpRx.gov directly, check your specific medication's eligibility, and verify whether your insurance status qualifies you for the listed discounts before purchasing.

Disclaimer: This blog post is for informational purposes only and does not constitute medical or financial advice. Always consult your physician or healthcare provider before changing your prescription medication plan. Eligibility and pricing on TrumpRx.gov are subject to change and vary by medication and individual circumstances.